Clinical Trials Browser

Esophageal Squamous Cell Carcinoma × durvalumab × Clear all

Esophageal Squamous Cell Carcinoma

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04568200 2024-01-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Completed

60 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04851132 2021-06-22

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Phase NA Unknown

33 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03377400 2020-12-17

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Phase 2 Unknown

40 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04054518 2019-08-13

DESC

Phase 2 Unknown

22 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Clinical Trials

KUNLUN

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

DESC